



**SDI FINAL EVALUATION FORM 1.1**

**PART 1:**

Journal Name:	<a href="#">International Blood Research &amp; Reviews</a>
Manuscript Number:	Ms IBRR 36037
Title of the Manuscript:	Profile of CD4, Tumor necrosis factor alpha, Hematological parameters and prevalence of hematological cytopenia in HIV seropositive patients on Anti-retroviral therapy in university of port Harcourt teaching hospital.
New Title of the Manuscript:	Immunological and Hematological profile of HIV patients on Anti-retroviral therapy in Port Harcourt, Rivers State, Nigeria
Type of Article:	Original Research Article

**PART 2:**

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<ol style="list-style-type: none"> <li>1. There should be prior definition of abbreviations before their use in the manuscript. For example <b>AR</b>???</li> <li>2. Is "<b>reduced CD4</b>" the consequence of <b>CD4&lt;200</b>? CD4&lt;200 is by itself reduced CD4 level. (Can something be a consequence of itself???)</li> <li>3. Your sample size calculation should be based on your <b>surrogate (primary) marker</b> which is?</li> <li>4. Authors should make manuscript "<b>reader-friendly</b>" by meticulously revising it sentence-by-sentence. Emphasis should be placed on transitions, punctuation marks and their right placements in sentences because some flaws in the manuscript are a consequence of these inadequacies. They should also do a thorough word check for some minor spelling errors.</li> <li>5. Authors should be watchful against the persistent use of "<b>makers</b>" in the place of "<b>markers</b>" when referring to the study parameters.</li> <li>6. <b>Frequencies</b> and <b>percentages</b> in the table of demographic data should be accompanied with their respective formulas; readers need all these details.</li> </ol>	

**Reviewer Details:**

Name:	<b>Tabé Franklin Nyenty</b>
Department, University & Country	<b>Department Of Biomedical Sciences, University Of Ngaoundere, Cameroon</b>